Neuroblasztóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• MYCN 0
• AKT 0
• TP53 0
• ALK 3
• B7-H3 7
• ERK 0
• PI3K 0
• MAPK 1
• SNCA 0
• mTOR 0
• NRF2 0
• NRAS 0
• AMPK 0
• BCL-2 0
• EZH2 0
• JNK 0
• KRAS 0
• MYC 0
• PPAR 0
• STAT3 0
• STING 1
• CDK4/6 0
• NTRK 0
• RAS 1
• SIRT1 0
• CD19 3
• PARP 2
• TDP-43 0
• VEGF 1
• BDNF 0
• HDAC 0
• HMGB1 0
• ROS1 1
• YAP 0
• BRAF 0
• FAK 0
• HIF-1 0
• IL-1 0
• IL-15 3
• MEK 0
• NLRP3 0
• PINK1 0
• PTEN 0
• APP 0
• BACE1 0
• CD47 0
• CGRP 0
• EGFR 1
• FGFR 0
• GPX4 0
• IDH 1
• IL-6 0
• MAPT 0
• MDM2 0
• PD-1 0
• PD-L1 0
• RET 0
• SOD1 0
• TFEB 0
• TNF 0

850 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Developing GFRA2 as an optimal immunotherapeutic target for neuroblastoma and Ewing sarcoma

  Children's Hosp of Philadelphia· Philadelphia, Egyesült Államok· 109 364 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, Egyesült Államok· 1 174 824 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors

  Mabswitch, Inc.· Van Nuys, Egyesült Államok· 399 998 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NINDS · UG3

  Augmenting immunotherapy pharmacodynamics in glioma

  Mayo Clinic Rochester· Rochester, Egyesült Államok· 712 838 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R01

  Investigating the Molecular Effects of Social Deprivation on Neuroblastoma Tumorigenesis and Progression

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 558 294 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours (PHOENIX)

  Fundacio Hospital Universitari Vall D'hebron - Institut de Recerca· Barcelona, Spanyolország· EU contribution 8 468 780 EUR· until 2032. máj.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  CamoUflaged nanopaRticle-driven duAl Therapy to eradicate aggressIVe nEuroblastoma (CURATIVE)

  Universidad de Navarra· Pamplona, Spanyolország· EU contribution 194 075 EUR· until 2028. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Engineered Nanomaterials as Adjuvants to Boost Neuroblastoma Vaccine Efficacy (NANO-ADJUVANT)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 268 569 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Olaszország· EU contribution 2 497 392 EUR· until 2030. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  EURopean Epitranscriptomics of Cancer Academy (EURECA)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 4 157 935 EUR· until 2029. okt.· 8 countries

10 of 209 running projects, newest first. Listed amounts together: 165,2 M USD + 57,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

  NCT04539366· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Other - review of safety data”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

  NCT06858501· Children's Oncology Group· Frissítve: 2026. szept. 16.

  “Other - Protocol moved to Withdrawn”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· National Cancer Institute (NCI)· Frissítve: 2026. jún. 30.

  “Drug supply issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

  NCT05130255· Y-mAbs Therapeutics· Frissítve: 2026. jún. 18.

  “Decision by Sponsor”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

  NCT04023331· Clarity Pharmaceuticals Ltd· Frissítve: 2025. szept. 16.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

  NCT03165292· Gustave Roussy, Cancer Campus, Grand Paris· Frissítve: 2025. szept. 2.

  “The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  9-ING-41 in Pediatric Patients With Refractory Malignancies.

  NCT04239092· Actuate Therapeutics Inc.· Frissítve: 2025. júl. 17.

  “The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

  NCT04530487· M.D. Anderson Cancer Center· Frissítve: 2025. jún. 29.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  GVAX Plus Checkpoint Blockade in Neuroblastoma

  NCT04239040· Dana-Farber Cancer Institute· Frissítve: 2025. márc. 19.

  “Manufacturing issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

  NCT04897880· Australian & New Zealand Children's Haematology/Oncology Group· Frissítve: 2025. febr. 24.

  “Drug supply”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Forrás

• Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  NCT06831552· Dana-Farber Cancer Institute· Forrás

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· National Cancer Institute (NCI)· Forrás

• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

  NCT04195555· National Cancer Institute (NCI)· Forrás

• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

  NCT04539366· National Cancer Institute (NCI)· Forrás

• A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

  NCT04936529· Memorial Sloan Kettering Cancer Center· Forrás

• A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

  NCT06057948· Memorial Sloan Kettering Cancer Center· Forrás

• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

  NCT06041516· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

  NCT07437963· National Cancer Institute (NCI)· Forrás

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 45
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 3
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 21
• Machine Learning 12
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• LC-MS-Based Metabolomic Profiling of Excoecaria agallocha Leaf Extract: Integrated Antioxidant, Anti-Inflammatory, Cholinesterase Inhibitory and Neuroprotective Evaluation with AChE-Targeted Molecular Docking.

  Molecules, 2026. okt.

• Carotenoid-Rich Pigment Extract From Micrococcus terreus SK34 Induces Apoptosis in SH-SY5Y Neuroblastoma Cells: Integrated Metabolomic, Molecular Docking, and Experimental Validation.

  Microbiologyopen, 2026. okt.

• Deciphering the metabolic landscape of MYCN non-amplified neuroblastoma through integrated multiomics.

  FEBS J, 2026. jún.

• Metabolomics reveals formonetin mitigates neurotoxicity of CL-20 on neuron cells.

  Drug Chem Toxicol, 2026. máj.

• Investigation into the metabolomic effects of the non-canonical amino acid azetidine-2-carboxylic acid in neuroblastoma cells.

  Food Chem Toxicol, 2026. máj.

• In vitro metabolomics for the characterization of drugs of abuse and new psychoactive substances in SH-SY5Y cells.

  Environ Toxicol Pharmacol, 2026. ápr.

• Analyzing Nicotine Action Against Amyloid Toxicity by NMR-Pharmacometabolomics: An Exploratory Study.

  NMR Biomed, 2026. ápr.

• Feruloyl substitution is associated with distinct neurogenic and metabolic signatures in cinnamoylquinic acid derivatives: An integrated transcriptomic-metabolomic analysis.

  Biomed Pharmacother, 2026. márc.

• Metabolomics-guided identification of bioactive phytometabolites from South African plants targeting neuroblastoma.

  Exp Biol Med (Maywood), 2026. márc.

• Molecular Insights of Neuroprotective Effect of Cornulaca monacantha Extract Against LPS-Induced Neuroinflammation Supported by Metabolic Profiling and Protein Interaction Analysis.

  Int J Mol Sci, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.